France· FR:69505243
ENJAYMO 50 mg/ml, solution pour perfusion
A medicinal product containing sutimlimab, registered in France by RECORDATI RARE DISEASES.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- SUTIMLIMAB
- Manufacturer
- RECORDATI RARE DISEASES
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009302665641 flacon(s) en verre de 22 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sutimlimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsEnjaymo 50mg/ml, oplossing voor infusieRecordati Rare Diseases
- SwitzerlandEnjaymo 1100 mg/22 ml, InfusionslösungRECORDATI AG
- CzechiaENJAYMORecordati Rare Diseases, Puteaux
- FinlandEnjaymoRecordati Rare Diseases
- IrelandEnjaymo 50 mg/mL solution for infusionRecordati Rare Diseases
- IcelandEnjaymoRecordati Rare Diseases
- Japanスチムリマブ（遺伝子組換え）レコルダティ・レア・ディジーズ・ジャパン
- NorwayEnjaymoRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enjaymo
- Liechtenstein · Enjaymo
- Norway · Enjaymo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eeace2c0-aa61-4312-b7b4-7ba78a2adbac GET /v1/drugs/eeace2c0-aa61-4312-b7b4-7ba78a2adbac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69505243",
"date_amm": "2022-11-15",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/22/1687",
"substance": "SUTIMLIMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about sutimlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.